A phase I/II trial of next generation formulation of PAN 90806 in patients with neovacular age-related macular degeneration

Trial Profile

A phase I/II trial of next generation formulation of PAN 90806 in patients with neovacular age-related macular degeneration

Planning
Phase of Trial: Phase I/II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs PAN 90806 (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Oct 2017 According to a PanOptica media release, this trial is expected to initiated in early 2018.
    • 06 Oct 2017 Planned initiation date changed from 1 Jan 2017 to 1 Jan 2018, according to a PanOptica media release.
    • 28 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top